According to the latest data from the Hong Kong Stock Exchange, on May 21, BlackRock increased its holdings in Innovent Bio (01801) by 369,453 shares. The transaction was executed at an average price of approximately HK$82.07 per share, amounting to a total consideration of about HK$30.32 million. Following this acquisition, BlackRock's total shareholding in the company has risen to approximately 87.28 million shares, representing a stake of 5.02%.